PT  - JOURNAL ARTICLE
AU  - Xiao, Fei
AU  - Tang, Meiwen
AU  - Zheng, Xiaobin
AU  - Li, Chunna
AU  - He, Jianzhong
AU  - Hong, Zhongsi
AU  - Huang, Siwen
AU  - Zhang, Zhenyi
AU  - Lin, Xianqi
AU  - Fang, Zhaoxiong
AU  - Lai, Renxu
AU  - Chen, Shoudeng
AU  - Liu, Jing
AU  - Huang, Jin
AU  - Xia, Jinyu
AU  - Li, Zhonghe
AU  - Jiang, Guanmin
AU  - Liu, Ye
AU  - Li, Xiaofeng
AU  - Shan, Hong
TI  - Evidence for gastrointestinal infection of SARS-CoV-2
AID  - 10.1101/2020.02.17.20023721
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.17.20023721
4099  - http://medrxiv.org/content/early/2020/02/20/2020.02.17.20023721.short
4100  - http://medrxiv.org/content/early/2020/02/20/2020.02.17.20023721.full
AB  - The new coronavirus (SARS-CoV-2) outbreak originating from Wuhan, China, poses a threat to global health. While it’s evident that the virus invades respiratory tract and transmits from human to human through airway, other viral tropisms and transmission routes remain unknown. We tested viral RNA in stool from 73 SARS-CoV-2-infected hospitalized patients using rRT-PCR. 53.42% of the patients tested positive in stool. 23.29% of the patients remained positive in feces even after the viral RNA decreased to undetectable level in respiratory tract. The viral RNA was also detected in gastrointestinal tissues. Furthermore, gastric, duodenal and rectal epithelia showed positive immunofluorescent staining of viral host receptor ACE2 and viral nucleocapsid protein in a case of SARS-CoV-2 infection. Our results provide evidence for gastrointestinal infection of SARS-CoV-2, highlighting its potential fecal-oral transmission route.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the National Natural Science Foundation of China (grant 81870411). The funders had no involvement in study design, writing the report or decision for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.